Fusion Pharmaceuticals to Acquire a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer Phase II Program

(24/7 MARKET NEWS) – Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) announced, after yesterday’s market close, the acquisition from RadioMedix, Inc. of the investigational new drug application (“IND”) for an ongoing Phase 2 clinical trial evaluating 225Ac-PSMA I&T, a small molecule targeting prostate specific membrane antigen (“PSMA”) expressed on prostate cancers. Following the closing, the alpha-emitting radiopharmaceutical being evaluated in the TATCIST trial will be known as FPI-2265.

Fusion Pharmaceuticals is at $4.19, up $0.57 (15.75%), on 750 thousand premarket shares.

Its 52-week trading range is $1.98 to $8.65. It hit  premarket high of $5.14 and has minimal resistance to the $7+ level.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist